Biogen (NASDAQ:BIIB) Raised to Hold at Barclays

Biogen (NASDAQ:BIIB) was upgraded by Barclays to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Several other brokerages have also weighed in on BIIB. Stifel Nicolaus lifted their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Wells Fargo & Company raised their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Sunday, February 8th. Mizuho lifted their price objective on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a research note on Monday, February 9th. Finally, Tudor Pickering set a $201.00 target price on Biogen in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Biogen has a consensus rating of “Hold” and an average target price of $205.04.

Biogen Stock Performance

BIIB opened at $192.03 on Thursday. The stock’s 50 day simple moving average is $180.02 and its 200-day simple moving average is $161.10. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock has a market cap of $28.18 billion, a PE ratio of 21.80, a P/E/G ratio of 1.52 and a beta of 0.16. Biogen has a 1 year low of $110.04 and a 1 year high of $202.41.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period last year, the business earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts forecast that Biogen will post 15.83 EPS for the current year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Institutional Trading of Biogen

A number of hedge funds and other institutional investors have recently made changes to their positions in BIIB. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen in the second quarter valued at about $25,000. WPG Advisers LLC increased its position in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares in the last quarter. Rothschild Investment LLC raised its stake in shares of Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares during the last quarter. Accredited Wealth Management LLC lifted its position in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares in the last quarter. Finally, First Horizon Corp acquired a new position in shares of Biogen during the fourth quarter worth approximately $30,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.